摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(R)-3-methoxydecyl p-toluenesulfonate

中文名称
——
中文别名
——
英文名称
(R)-3-methoxydecyl p-toluenesulfonate
英文别名
(R)-3-methoxydecyl tosylate;[(3R)-3-methoxydecyl] 4-methylbenzenesulfonate
(R)-3-methoxydecyl p-toluenesulfonate化学式
CAS
——
化学式
C18H30O4S
mdl
——
分子量
342.5
InChiKey
SFFNFTMWTPDUJI-QGZVFWFLSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    5.3
  • 重原子数:
    23
  • 可旋转键数:
    12
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.67
  • 拓扑面积:
    61
  • 氢给体数:
    0
  • 氢受体数:
    4

反应信息

  • 作为反应物:
    描述:
    (R)-3-methoxydecyl p-toluenesulfonate吡啶potassium tert-butylate对甲苯磺酸一水合物 、 sodium hydride 、 碳酸氢钠 作用下, 以 四氢呋喃甲醇二氯甲烷二甲基亚砜N,N-二甲基甲酰胺 为溶剂, 反应 16.5h, 生成 (Z)-prop-1-enyl 6-O-(allyloxycarbonyl)-2-deoxy-3-O-[(R)-3-methoxydecyl]-2-[(2,2,2-trichloroethoxycarbonyl)amino]-β-D-glucopyranoside
    参考文献:
    名称:
    Synthesis of lipid A analogues containing glucose instead of glucosamine and their LPS-antagonistic activities
    摘要:
    Lipid A analogues containing glucose in substitution for glucosamine on the reducing end were synthesized, and the inhibitory activities on LPS-induced TNF alpha production (LPS-antagonistic activity) in vitro using human whole blood cells were measured. The IC50 values (nM) of these ten compounds, 8, 14, 21, 31, 40, 51, 57, 62, 67 and 72, were 11.2, 15.4, 2.7, 0.1, 0.4, 1.3, 3.2, 3.2, 1.4 and 14.4, respectively. And also inhibitory activities (ID50) on TNF alpha production toward galactosamine loaded C3H/HeN mice in vivo of compounds 21, 31, 57, 62 and 67 were measured. The values of these compounds were 0.29, 0.50, 0.61, not dose-dependent and 0.33 mg/kg, respectively. (c) 2005 Elsevier Ltd. All rights reserved.
    DOI:
    10.1016/j.tet.2005.03.034
点击查看最新优质反应信息

文献信息

  • Sodium salt of disaccharide compound, production method and use of same
    申请人:Sakurai Shin
    公开号:US20080227991A1
    公开(公告)日:2008-09-18
    The present invention relates to a sodium salt represented by average formula (I): (wherein, m 1 , n 1 , m 2 and n 2 respectively and independently represent a positive number of 0 0r 2 or less, provided that m 1 +n 1 =2, m 2 +n 2 =2, 0
    本发明涉及一种由平均式(I)表示的钠盐:(其中,m1、n1、m2和n2分别独立地表示00r2或更小的正数,前提是m1+n1=2,m2+n2=2,0
  • Left-Side Glucose Lipid a Analogue
    申请人:Shiozaki Masao
    公开号:US20090062214A1
    公开(公告)日:2009-03-05
    A compound having excellent macrophage activity inhibitory action, which is represented by the general following formula: wherein Q represents an oxygen atom, a C 1 -C 3 alkylene group, a —O-Alk- group or a —O-Alk-O— group (in which Alk is a C 1 -C 3 alkylene group), R 1 represents a C 1 -C 20 alkanoyl group which may be substituted, a C 3 -C 20 alkenoyl group which may be substituted or a C 3 -C 20 alkynoyl group which may be substituted, R 2 , R 3 and R 4 , which may be the same or different, represent a hydrogen atom, a C 1 -C 20 alkyl group which may be substituted, a C 2 -C 20 alkenyl group which may be substituted, a C 2 -C 20 alkynyl group which may be substituted, a C 1 -C 20 alkanoyl group which may be substituted, a C 3 -C 20 alkenoyl group which may be substituted or a C 3 -C 20 alkynoyl group which may be substituted, R 5 represents a hydrogen atom, a halogen atom, a hydroxyl group, a C 1 -C 6 alkoxy group which may be substituted, a C 2 -C 6 alkenyloxy group which may be substituted or a C 2 -C 6 alkynyloxy group which may be substituted, and W represents an oxygen atom or a —NH— group, or a pharmacologically acceptable salt thereof.
    一种具有出色的巨噬细胞活性抑制作用的化合物,其通式如下:其中,Q代表氧原子、C1-C3烷基、—O-Alk-基团或—O-Alk-O—基团(其中,Alk代表C1-C3烷基),R1代表C1-C20烷酰基,可以被取代的C3-C20烯酰基或可以被取代的C3-C20炔酰基,R2、R3和R4,可以相同也可以不同,代表氢原子、可以被取代的C1-C20烷基、可以被取代的C2-C20烯基、可以被取代的C2-C20炔基、可以被取代的C1-C20烷酰基、可以被取代的C3-C20烯酰基或可以被取代的C3-C20炔酰基,R5代表氢原子、卤原子、羟基、可以被取代的C1-C6烷氧基、可以被取代的C2-C6烯氧基或可以被取代的C2-C6炔氧基,W代表氧原子或—NH—基团,或其药学上可接受的盐。
  • LEVULOSE GLUCOSELIPID A ANALOGUE
    申请人:Sankyo Company, Limited
    公开号:EP1702926A1
    公开(公告)日:2006-09-20
    A compound having excellent macrophage activity inhibitory action, which is represented by the general following formula: [wherein Q represents an oxygen atom, a C1-C3 alkylene group, a -O-Alk- group or a -O-Alk-O- group (in which Alk is a C1-C3 alkylene group), R1 represents a C1-C20 alkanoyl group which may be substituted, a C3-C20 alkenoyl group which may be substituted or a C3-C20 alkynoyl group which may be substituted, R2, R3 and R4, which may be the same or different, represent a hydrogen atom, a C1-C20 alkyl group which may be substituted, a C2-C20 alkenyl group which may be substituted, a C2-C20 alkynyl group which may be substituted, a C1-C20 alkanoyl group which may be substituted, a C3-C20 alkenoyl group which may be substituted or a C3-C20 alkynoyl group which may be substituted, R5 represents a hydrogen atom, a halogen atom, a hydroxyl group, a C1-C6 alkoxy group which may be substituted, a C2-C6 alkenyloxy group which may be substituted or a C2-C6 alkynyloxy group which may be substituted, and W represents an oxygen atom or a -NH- group], or a pharmacologically acceptable salt thereof.
    一种具有优异的巨噬细胞活性抑制作用的化合物,其通式如下: [其中 Q 代表氧原子、C1-C3 亚烷基、-O-Alk- 基团或 -O-Alk-O- 基团(其中 Alk 为 C1-C3 亚烷基)、 R1 代表可被取代的 C1-C20 烷酰基、可被取代的 C3-C20 烯酰基或可被取代的 C3-C20 炔酰基、 R2、R3 和 R4(可以相同或不同)代表氢原子、可被取代的 C1-C20 烷基、可被取代的 C2-C20 烯基、可被取代的 C2-C20 烷炔基、可被取代的 C1-C20 烷酰基、可被取代的 C3-C20 烯酰基或可被取代的 C3-C20 烷炔基、 R5 代表氢原子、卤素原子、羟基、可被取代的 C1-C6 烷氧基、可被取代的 C2-C6 烯氧基或可被取代的 C2-C6 烷炔氧基,以及 W 代表氧原子或-NH-基团],或其药理学上可接受的盐。
  • EP1702926
    申请人:——
    公开号:——
    公开(公告)日:——
  • Syntheses of glucose-containing E5564 analogues and their LPS-antagonistic activities
    作者:Masao Shiozaki、Hiromi Doi、Daisuke Tanaka、Takaichi Shimozato、Shin-ichi Kurakata
    DOI:10.1016/j.tet.2005.09.115
    日期:2006.1
    Lipid A analogues containing a glucose moiety on their non-reducing end were synthesized, and their LPS-antagonistic activities were measured. The inhibitory activities (IC50) on LPS-induced TNF alpha production of these six compounds, 26, 33, 440, 520, 59, and 61, toward human whole blood cells were 0.49, 0.65, 0.51, 0.98, 0.46, and 1.11 nM, respectively. Inhibitory doses (ID50) of compounds 26, 33, 440, 59, and 61 on TNF alpha production induced by coinjection of galactosamine and LPS in C3HMeN mice were measured. The ID50 values of these compounds were 0.45, 0.96, < 0.2, 1.08, and < 0.2 mg/kg, respectively. Moreover, C3H/HeN mice preinjected with compounds 26, 33, and 440 were protected from lethality induced by coinjection of galactosamine and LPS. Out of eight mice preinjected with 1 mg/kg of compounds 26, 33, and 440, five, eight and six mice were protected, respectively. (c) 2005 Elsevier Ltd. All rights reserved.
查看更多

同类化合物

(βS)-β-氨基-4-(4-羟基苯氧基)-3,5-二碘苯甲丙醇 (S)-(-)-7'-〔4(S)-(苄基)恶唑-2-基]-7-二(3,5-二-叔丁基苯基)膦基-2,2',3,3'-四氢-1,1-螺二氢茚 (S)-盐酸沙丁胺醇 (S)-3-(叔丁基)-4-(2,6-二甲氧基苯基)-2,3-二氢苯并[d][1,3]氧磷杂环戊二烯 (S)-2,2'-双[双(3,5-三氟甲基苯基)膦基]-4,4',6,6'-四甲氧基联苯 (S)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (R)富马酸托特罗定 (R)-(-)-盐酸尼古地平 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[((6-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-3-(叔丁基)-4-(2,6-二苯氧基苯基)-2,3-二氢苯并[d][1,3]氧杂磷杂环戊烯 (R)-2-[((二苯基膦基)甲基]吡咯烷 (N-(4-甲氧基苯基)-N-甲基-3-(1-哌啶基)丙-2-烯酰胺) (5-溴-2-羟基苯基)-4-氯苯甲酮 (5-溴-2-氯苯基)(4-羟基苯基)甲酮 (5-氧代-3-苯基-2,5-二氢-1,2,3,4-oxatriazol-3-鎓) (4S,5R)-4-甲基-5-苯基-1,2,3-氧代噻唑烷-2,2-二氧化物-3-羧酸叔丁酯 (4-溴苯基)-[2-氟-4-[6-[甲基(丙-2-烯基)氨基]己氧基]苯基]甲酮 (4-丁氧基苯甲基)三苯基溴化磷 (3aR,8aR)-(-)-4,4,8,8-四(3,5-二甲基苯基)四氢-2,2-二甲基-6-苯基-1,3-二氧戊环[4,5-e]二恶唑磷 (2Z)-3-[[(4-氯苯基)氨基]-2-氰基丙烯酸乙酯 (2S,3S,5S)-5-(叔丁氧基甲酰氨基)-2-(N-5-噻唑基-甲氧羰基)氨基-1,6-二苯基-3-羟基己烷 (2S,2''S,3S,3''S)-3,3''-二叔丁基-4,4''-双(2,6-二甲氧基苯基)-2,2'',3,3''-四氢-2,2''-联苯并[d][1,3]氧杂磷杂戊环 (2S)-(-)-2-{[[[[3,5-双(氟代甲基)苯基]氨基]硫代甲基]氨基}-N-(二苯基甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[[((1R,2R)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2-硝基苯基)磷酸三酰胺 (2,6-二氯苯基)乙酰氯 (2,3-二甲氧基-5-甲基苯基)硼酸 (1S,2S,3S,5S)-5-叠氮基-3-(苯基甲氧基)-2-[(苯基甲氧基)甲基]环戊醇 (1-(4-氟苯基)环丙基)甲胺盐酸盐 (1-(3-溴苯基)环丁基)甲胺盐酸盐 (1-(2-氯苯基)环丁基)甲胺盐酸盐 (1-(2-氟苯基)环丙基)甲胺盐酸盐 (-)-去甲基西布曲明 龙胆酸钠 龙胆酸叔丁酯 龙胆酸 龙胆紫 龙胆紫 齐达帕胺 齐诺康唑 齐洛呋胺 齐墩果-12-烯[2,3-c][1,2,5]恶二唑-28-酸苯甲酯 齐培丙醇 齐咪苯 齐仑太尔 黑染料 黄酮,5-氨基-6-羟基-(5CI) 黄酮,6-氨基-3-羟基-(6CI) 黄蜡,合成物 黄草灵钾盐